Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Reference17 articles.
1. Jakobsen JA, Quattrocchi CC, Müller FHH et al (2021) Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study. BMC Med Imaging 21:74
2. Chazot A, Barrat J-A, Gaha M, Jomaah R, Ognard J, Ben SD (2020) Brain MRI make up the bulk of the gadolinium footprint in medical imaging. J Neuroradiol 47:259–265
3. Endrikat J, Dohanish S, Schleyer N, Schwenke S, Agarwal S, Balzer T (2018) 10 years of nephrogenic systemic fibrosis: a comprehensive analysis of nephrogenic systemic fibrosis reports received by a pharmaceutical company from 2006 to 2016. Invest Radiol 53:541–550
4. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834–841
5. European Medicines Agency. EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans (21 July 2017). https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-emas-final-opinion-confirms-restrictions-use-linear-gadolinium-agents_en-0.pdf. Accessed 20 Feb 2023